Aerovate Therapeutics Statistics
Total Valuation
AVTE has a market cap or net worth of $80.54 million. The enterprise value is -$22.98 million.
Important Dates
The next estimated earnings date is Monday, November 11, 2024, before market open.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AVTE has 28.87 million shares outstanding. The number of shares has increased by 13.63% in one year.
| Shares Outstanding | 28.87M |
| Shares Change (YoY) | +13.63% |
| Shares Change (QoQ) | +3.45% |
| Owned by Insiders (%) | 0.10% |
| Owned by Institutions (%) | 37.69% |
| Float | 11.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.85 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.51, with a Debt / Equity ratio of 0.01.
| Current Ratio | 6.51 |
| Quick Ratio | 6.12 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -74.42% and return on invested capital (ROIC) is -49.51%.
| Return on Equity (ROE) | -74.42% |
| Return on Assets (ROA) | -44.04% |
| Return on Capital (ROIC) | -49.51% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.72M |
| Employee Count | 51 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AVTE has paid $56,000 in taxes.
| Income Tax | 56,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.70% in the last 52 weeks. The beta is 1.03, so AVTE's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | -73.70% |
| 50-Day Moving Average | 2.06 |
| 200-Day Moving Average | 12.27 |
| Relative Strength Index (RSI) | 73.58 |
| Average Volume (20 Days) | 1,940,838 |
Short Selling Information
The latest short interest is 664,994, so 2.30% of the outstanding shares have been sold short.
| Short Interest | 664,994 |
| Short Previous Month | 846,446 |
| Short % of Shares Out | 2.30% |
| Short % of Float | 5.61% |
| Short Ratio (days to cover) | 2.99 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -94.22M |
| Pretax Income | -82.13M |
| Net Income | -87.94M |
| EBITDA | -94.11M |
| EBIT | -94.22M |
| Earnings Per Share (EPS) | -$3.13 |
Full Income StatementBalance Sheet
The company has $104.20 million in cash and $681,000 in debt, giving a net cash position of $103.52 million or $3.59 per share.
| Cash & Cash Equivalents | 104.20M |
| Total Debt | 681,000 |
| Net Cash | 103.52M |
| Net Cash Per Share | $3.59 |
| Equity (Book Value) | 94.40M |
| Book Value Per Share | 3.27 |
| Working Capital | 93.74M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$74.52 million and capital expenditures -$96,000, giving a free cash flow of -$74.61 million.
| Operating Cash Flow | -74.52M |
| Capital Expenditures | -96,000 |
| Free Cash Flow | -74.61M |
| FCF Per Share | -$2.58 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |